Please assess the completion status of the following clinical trial:

Trial Title: Treosulfan Based Conditioning Acute Myeloid Leukaemia (AML)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with acute myeloid leukaemia (AML) according to WHO classification (\> 20% myeloblasts in peripheral blood or bone marrow at initial diagnosis) with \< 5% myeloblast in the bone marrow, indicated for allogeneic transplantation~* Availability of an HLA-identical sibling donor (MRD) or HLA-identical unrelated donor (MUD) HLA-identity defined by the following markers: A, B, DRB1, DQB1.~* Target graft size (unmanipulated)~* bone marrow: 2 - 10 x 106 CD34+ cells/kg BW recipient or \> 2 x 108 nucleated cells/kg BW recipient or~* peripheral blood: 4 - 10 x 106 CD34+ cells/kg BW recipient~* Age \> 18 and \< 60 years~* Karnofsky Index \> 80 %~* Adequate contraception in female patients of child-bearing potential~* Written informed consent~Exclusion Criteria:~* Therapy related secondary AML~* AML with t(8;21)(q22;q22) in CR1~* Acute promyelocytic leukaemia with t(15;17)(q22;q12) in CR1~* Secondary malignancies~* Previous allogeneic transplantation~* Severe concomitant illnesses / medical conditions (e.g. impaired respiratory and/or cardiac function)~* Known and manifested malignant involvement of the CNS~* Active infectious disease~* HIV- positivity or active hepatitis infection~* Impaired liver function (Bilirubin \> upper normal limit; Transaminases \> 3.0 x upper normal limit)~* Impaired renal function (Creatinine-clearance \< 60 ml/min; Serum Creatinine \> 1.5 x upper normal limit).~* Pleural effusion or ascites \> 1.0 L~* Pregnancy or lactation~* Known hypersensitivity to treosulfan and/or fludarabine~* Participation in another experimental drug trial within 4 weeks before day -6~* Non-co-operative behaviour or non-compliance~* Psychiatric diseases or conditions that might impair the ability to give informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Treosulfan (Type: EXPERIMENTAL): Patients with acute myeloid leukaemia (AML) according to WHO classification (\> 20% myeloblasts in peripheral blood or bone marrow at initial diagnosis) with \< 5% myeloblasts in the bone marrow, indicated for allogeneic transplantation

Based on this trial design, predict the completion outcome and termination type (if applicable).